Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the ...
News Medical on MSN22h
Breakthrough in immunology: AbMAP’s novel approach to antibody modelingResearchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, ...
Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity—primarily organ transplant ...
An MOH spokesman said that in general, the Covid-19 situation here has been stable. Read more at straitstimes.com.
When children receive their second measles-mumps-rubella vaccine, around the time they start kindergarten, they gain ...
News Medical on MSN21h
CDC study highlights growing tularemia threat in central U.S.Tularemia cases in the U.S. rose by 56% from 2011 to 2022, with central states and American Indian communities most affected, ...
Regdanvimab is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.
The following is a summary of “Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and ...
A new test can differentiate between various types of asthma via a nasal swab. Researchers hope it can eventually help match ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback